{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T22:14:46Z","timestamp":1783548886619,"version":"3.55.0"},"reference-count":96,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T00:00:00Z","timestamp":1627516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Angiotensin receptor blockers (ARBs) can ameliorate metabolic syndrome (MetS)-associated dyslipidemia, hepatic steatosis, and glucose intolerance, suggesting that angiotensin receptor (AT1) over-activation contributes to impaired lipid and glucose metabolism, which is characteristic of MetS. The aim of this study was to evaluate changes in the lipid profile and proteins of fatty acid uptake, triacylglycerol (TAG) synthesis, and \u03b2-oxidation to better understand the links between AT1 overactivation and non-alcoholic fatty liver disease (NAFLD) during MetS.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Four groups of 25-week-old-rats were used: (1) untreated LETO, (2) untreated OLETF, (3) OLETF\u2009+\u2009angiotensin receptor blocker (ARB; 10\u2009mg olmesartan\/kg\/d\u2009\u00d7\u20098 weeks) and (4) OLETF\u2009\u00b1\u2009ARB (MINUS; 10\u2009mg olmesartan\/kg\/d\u2009\u00d7\u20094 weeks, then removed until dissection). To investigate the dynamic shifts in metabolism, animals were dissected after an oral glucose challenge (fasting, 3 and 6\u2009h post-glucose).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared to OLETF, plasma total cholesterol and TAG remained unchanged in ARB. However, liver TAG was 55% lesser in ARB than OLETF, and remained lower throughout the challenge. Basal CD36 and ApoB were 28% and 29% lesser, respectively, in ARB than OLETF. PRDX6 abundance in ARB was 45% lesser than OLETF, and it negatively correlated with liver TAG in ARB.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Chronic blockade of AT1 protects the liver from TAG accumulation during glucose overload. This may be achieved by modulating NEFA uptake and increasing TAG export via ApoB. Our study highlights the contributions of AT1 signaling to impaired hepatic substrate metabolism and the detriments of a high-glucose load and its potential contribution to steatosis during MetS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s12020-021-02834-7","type":"journal-article","created":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T19:08:41Z","timestamp":1627585721000},"page":"92-107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Chronic angiotensin receptor activation promotes hepatic triacylglycerol accumulation during an acute glucose challenge in obese-insulin-resistant OLETF rats"],"prefix":"10.1007","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4671-3201","authenticated-orcid":false,"given":"Jose A.","family":"Godoy-Lugo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max A.","family":"Thorwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David Y.","family":"Hui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose G.","family":"So\u00f1anez-Organis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudy M.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,29]]},"reference":[{"key":"2834_CR1","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1053\/j.gastro.2020.01.052","volume":"158","author":"TG Cotter","year":"2020","unstructured":"T.G. Cotter, M. Rinella, Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology 158, 1851\u20131864 (2020)","journal-title":"Gastroenterology"},{"key":"2834_CR2","doi-asserted-by":"publisher","first-page":"G697","DOI":"10.1152\/ajpgi.00426.2010","volume":"300","author":"DJ Chiang","year":"2011","unstructured":"D.J. Chiang, M.T. Pritchard, L.E. Nagy, Obesity, diabetes mellitus, and liver fibrosis. Am J Physiol Gastrointest Liver Physiol 300, G697\u2013G702 (2011)","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2834_CR3","first-page":"9","volume":"13","author":"P Paschos","year":"2009","unstructured":"P. Paschos, K. Paletas, Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 13, 9\u201319 (2009)","journal-title":"Hippokratia"},{"key":"2834_CR4","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","volume":"112","author":"SM Grundy","year":"2005","unstructured":"S.M. Grundy, J.I. Cleeman, S.R. Daniels, K.A. Donato, R.H. Eckel et al. Diagnosis and management of the metabolic syndrome: an American Heart Association\/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112, 2735\u20132752 (2005)","journal-title":"Circulation"},{"key":"2834_CR5","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.mce.2012.04.013","volume":"378","author":"E Matthew Morris","year":"2013","unstructured":"E. Matthew Morris, J.A. Fletcher, J.P. Thyfault, R.S. Rector, The role of angiotensin II in nonalcoholic steatohepatitis. Mol Cell Endocrinol 378, 29\u201340 (2013)","journal-title":"Mol Cell Endocrinol"},{"key":"2834_CR6","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.jhep.2008.03.018","volume":"49","author":"Y Wei","year":"2008","unstructured":"Y. Wei, S.E. Clark, E.M. Morris, J.P. Thyfault, G.M. Uptergrove et al. Angiotensin II-induced non-alcoholic fatty liver disease is mediated by oxidative stress in transgenic TG(mRen2)27(Ren2) rats. J Hepatol 49, 417\u2013428 (2008)","journal-title":"J Hepatol"},{"key":"2834_CR7","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.mce.2008.12.011","volume":"302","author":"JA Olivares-Reyes","year":"2009","unstructured":"J.A. Olivares-Reyes, A. Arellano-Plancarte, J.R. Castillo-Hernandez, Angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol 302, 128\u2013139 (2009)","journal-title":"Mol Cell Endocrinol"},{"key":"2834_CR8","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1161\/hy1101.092970","volume":"38","author":"EJ Henriksen","year":"2001","unstructured":"E.J. Henriksen, S. Jacob, T.R. Kinnick, M.K. Teachey, M. Krekler, Selective angiotensin II receptor antagonism reduces insulin resistance in obese Zucker rats. Hypertension 38, 884\u2013890 (2001)","journal-title":"Hypertension"},{"key":"2834_CR9","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1016\/j.metabol.2005.06.016","volume":"54","author":"JA Sloniger","year":"2005","unstructured":"J.A. Sloniger, V. Saengsirisuwan, C.J. Diehl, J.S. Kim, E.J. Henriksen, Selective angiotensin II receptor antagonism enhances whole-body insulin sensitivity and muscle glucose transport in hypertensive TG(mREN2)27 rats. Metabolism 54, 1659\u20131668 (2005)","journal-title":"Metabolism"},{"key":"2834_CR10","doi-asserted-by":"publisher","first-page":"5647161","DOI":"10.1155\/2019\/5647161","volume":"2019","author":"Y Li","year":"2019","unstructured":"Y. Li, F. Xiong, W. Xu, S. Liu, Increased serum angiotensin II is a risk factor of nonalcoholic fatty liver disease: a prospective pilot study. Gastroenterol Res Pract 2019, 5647161 (2019)","journal-title":"Gastroenterol Res Pract"},{"key":"2834_CR11","doi-asserted-by":"publisher","first-page":"E955","DOI":"10.1152\/ajpendo.00199.2004","volume":"287","author":"J Ran","year":"2004","unstructured":"J. Ran, T. Hirano, M. Adachi, Chronic ANG II infusion increases plasma triglyceride level by stimulating hepatic triglyceride production in rats. Am J Physiol Endocrinol Metab 287, E955\u2013E961 (2004)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2834_CR12","doi-asserted-by":"publisher","first-page":"E227","DOI":"10.1152\/ajpendo.00090.2004","volume":"287","author":"J Ran","year":"2004","unstructured":"J. Ran, T. Hirano, M. Adachi, Angiotensin II type 1 receptor blocker ameliorates overproduction and accumulation of triglyceride in the liver of Zucker fatty rats. Am J Physiol Endocrinol Metab 287, E227\u2013E232 (2004)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2834_CR13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/08998280.2003.11927893","volume":"16","author":"A Barreras","year":"2003","unstructured":"A. Barreras, C. Gurk-Turner, Angiotensin II receptor blockers. Proc Bayl Univ Med Cent 16, 123\u2013126 (2003)","journal-title":"Proc Bayl Univ Med Cent"},{"key":"2834_CR14","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/157016111794519318","volume":"9","author":"S Yamada","year":"2011","unstructured":"S. Yamada, Pleiotropic effects of ARB in metabolic syndrome. Curr Vasc Pharmacol 9, 158\u2013161 (2011)","journal-title":"Curr Vasc Pharmacol"},{"key":"2834_CR15","doi-asserted-by":"publisher","first-page":"24155","DOI":"10.18632\/oncotarget.23816","volume":"9","author":"Y Li","year":"2018","unstructured":"Y. Li, H. Xu, W. Wu, J. Ye, D. Fang et al. Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Oncotarget 9, 24155\u201324167 (2018)","journal-title":"Oncotarget"},{"key":"2834_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s41440-018-0040-6","volume":"41","author":"LMA Borem","year":"2018","unstructured":"L.M.A. Borem, J.F.R. Neto, I.V. Brandi, D.F. Lelis, S.H.S. Santos, The role of the angiotensin II type I receptor blocker telmisartan in the treatment of non-alcoholic fatty liver disease: a brief review. Hypertens Res 41, 394\u2013405 (2018)","journal-title":"Hypertens Res"},{"key":"2834_CR17","first-page":"21","volume":"47","author":"SM Kyvelou","year":"2006","unstructured":"S.M. Kyvelou, G.P. Vyssoulis, E.A. Karpanou, D.N. Adamopoulos, A.I. Zervoudaki et al. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial. Hellenic J Cardiol 47, 21\u201328 (2006)","journal-title":"Hellenic J Cardiol"},{"key":"2834_CR18","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1177\/147323000102900402","volume":"29","author":"M Hanefeld","year":"2001","unstructured":"M. Hanefeld, C. Abletshauser, Effect of the angiotensin II receptor antagonist valsartan on lipid profile and glucose metabolism in patients with hypertension. J Int Med Res 29, 270\u2013279 (2001)","journal-title":"J Int Med Res"},{"key":"2834_CR19","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/hr.2013.3","volume":"36","author":"I Taguchi","year":"2013","unstructured":"I. Taguchi, S. Toyoda, K. Takano, T. Arikawa, M. Kikuchi et al. Irbesartan, an angiotensin receptor blocker, exhibits metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. Hypertens Res 36, 608\u2013613 (2013)","journal-title":"Hypertens Res"},{"key":"2834_CR20","doi-asserted-by":"publisher","first-page":"5746","DOI":"10.1210\/en.2012-1390","volume":"153","author":"P Montez","year":"2012","unstructured":"P. Montez, J.P. Vazquez-Medina, R. Rodriguez, M.A. Thorwald, J.A. Viscarra et al. Angiotensin receptor blockade recovers hepatic UCP2 expression and aconitase and SDH activities and ameliorates hepatic oxidative damage in insulin resistant rats. Endocrinology 153, 5746\u20135759 (2012)","journal-title":"Endocrinology"},{"key":"2834_CR21","doi-asserted-by":"publisher","first-page":"G1094","DOI":"10.1152\/ajpgi.00365.2010","volume":"300","author":"K Kaji","year":"2011","unstructured":"K. Kaji, H. Yoshiji, M. Kitade, Y. Ikenaka, R. Noguchi et al. Combination treatment of angiotensin II type I receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats. Am J Physiol Gastrointest Liver Physiol 300, G1094\u2013G1104 (2011)","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2834_CR22","doi-asserted-by":"publisher","first-page":"8625","DOI":"10.1073\/pnas.95.15.8625","volume":"95","author":"D Hirsch","year":"1998","unstructured":"D. Hirsch, A. Stahl, H.F. Lodish, A family of fatty acid transporters conserved from mycobacterium to man. Proc Natl Acad Sci USA 95, 8625\u20138629 (1998)","journal-title":"Proc Natl Acad Sci USA"},{"key":"2834_CR23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.3350\/cmh.2013.19.3.210","volume":"19","author":"SH Koo","year":"2013","unstructured":"S.H. Koo, Nonalcoholic fatty liver disease: molecular mechanisms for the hepatic steatosis. Clin Mol Hepatol 19, 210\u2013215 (2013)","journal-title":"Clin Mol Hepatol"},{"key":"2834_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s12944-018-0790-9","volume":"17","author":"J Liu","year":"2018","unstructured":"J. Liu, P. Yang, G. Zuo, S. He, W. Tan et al. Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress. Lipids Health Dis 17, 153 (2018)","journal-title":"Lipids Health Dis"},{"key":"2834_CR25","doi-asserted-by":"publisher","first-page":"E384","DOI":"10.1152\/ajpendo.00226.2010","volume":"299","author":"A Falcon","year":"2010","unstructured":"A. Falcon, H. Doege, A. Fluitt, B. Tsang, N. Watson et al. FATP2 is a hepatic fatty acid transporter and peroxisomal very long-chain acyl-CoA synthetase. Am J Physiol Endocrinol Metab 299, E384\u2013E393 (2010)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2834_CR26","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1053\/j.gastro.2006.02.006","volume":"130","author":"H Doege","year":"2006","unstructured":"H. Doege, R.A. Baillie, A.M. Ortegon, B. Tsang, Q. Wu et al. Targeted deletion of FATP5 reveals multiple functions in liver metabolism: alterations in hepatic lipid homeostasis. Gastroenterology 130, 1245\u20131258 (2006)","journal-title":"Gastroenterology"},{"key":"2834_CR27","doi-asserted-by":"publisher","first-page":"3313","DOI":"10.1007\/s00018-018-2860-6","volume":"75","author":"DH Ipsen","year":"2018","unstructured":"D.H. Ipsen, J. Lykkesfeldt, P. Tveden-Nyborg, Molecular mechanisms of hepatic lipid accumulation in non-alcoholic fatty liver disease. Cell Mol Life Sci 75, 3313\u20133327 (2018)","journal-title":"Cell Mol Life Sci"},{"key":"2834_CR28","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.bbrc.2005.08.070","volume":"336","author":"M Inoue","year":"2005","unstructured":"M. Inoue, T. Ohtake, W. Motomura, N. Takahashi, Y. Hosoki et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 336, 215\u2013222 (2005)","journal-title":"Biochem Biophys Res Commun"},{"key":"2834_CR29","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1136\/gut.2010.222844","volume":"60","author":"ME Miquilena-Colina","year":"2011","unstructured":"M.E. Miquilena-Colina, E. Lima-Cabello, S. Sanchez-Campos, M.V. Garcia-Mediavilla, M. Fernandez-Bermejo et al. Hepatic fatty acid translocase CD36 upregulation is associated with insulin resistance, hyperinsulinaemia and increased steatosis in non-alcoholic steatohepatitis and chronic hepatitis C. Gut 60, 1394\u20131402 (2011)","journal-title":"Gut"},{"key":"2834_CR30","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1089\/ars.2018.7544","volume":"31","author":"DH Lee","year":"2019","unstructured":"D.H. Lee, Y.Y. Jung, M.H. Park, M.R. Jo, S.B. Han et al. Peroxiredoxin 6 confers protection against nonalcoholic fatty liver disease through maintaining mitochondrial function. Antioxid Redox Signal 31, 387\u2013402 (2019)","journal-title":"Antioxid Redox Signal"},{"key":"2834_CR31","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1089\/ars.2010.3412","volume":"15","author":"AB Fisher","year":"2011","unstructured":"A.B. Fisher, Peroxiredoxin 6: a bifunctional enzyme with glutathione peroxidase and phospholipase A(2) activities. Antioxid Redox Signal 15, 831\u2013844 (2011)","journal-title":"Antioxid Redox Signal"},{"key":"2834_CR32","doi-asserted-by":"publisher","first-page":"G266","DOI":"10.1152\/ajpgi.90583.2008","volume":"296","author":"T Eismann","year":"2009","unstructured":"T. Eismann, N. Huber, T. Shin, S. Kuboki, E. Galloway et al. Peroxiredoxin-6 protects against mitochondrial dysfunction and liver injury during ischemia-reperfusion in mice. Am J Physiol Gastrointest Liver Physiol 296, G266\u2013G274 (2009)","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2834_CR33","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.biocel.2017.12.019","volume":"95","author":"ICM Simoes","year":"2018","unstructured":"I.C.M. Simoes, A. Fontes, P. Pinton, H. Zischka, M.R. Wieckowski, Mitochondria in non-alcoholic fatty liver disease. Int J Biochem Cell Biol 95, 93\u201399 (2018)","journal-title":"Int J Biochem Cell Biol"},{"key":"2834_CR34","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1152\/ajpendo.00192.2014","volume":"308","author":"CJ Green","year":"2015","unstructured":"C.J. Green, C. Pramfalk, K.J. Morten, L. Hodson, From whole body to cellular models of hepatic triglyceride metabolism: man has got to know his limitations. Am J Physiol Endocrinol Metab 308, E1\u2013E20 (2015)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2834_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1586\/egh.09.32","volume":"3","author":"N Alkhouri","year":"2009","unstructured":"N. Alkhouri, L.J. Dixon, A.E. Feldstein, Lipotoxicity in nonalcoholic fatty liver disease: not all lipids are created equal. Expert Rev Gastroenterol Hepatol 3, 445\u2013451 (2009)","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2834_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.freeradbiomed.2018.10.405","volume":"130","author":"MA Thorwald","year":"2019","unstructured":"M.A. Thorwald, J.A. Godoy-Lugo, G.J. Rodriguez, M.A. Rodriguez, M. Jamal et al. Nrf2-related gene expression is impaired during a glucose challenge in type II diabetic rat hearts. Free Radic Biol Med 130, 306\u2013317 (2019)","journal-title":"Free Radic Biol Med"},{"key":"2834_CR37","doi-asserted-by":"crossref","unstructured":"W. Kopp. How Western diet and lifestyle drive the pandemic of obesity and civilization diseases. Diabetes Metab Syndr Obes 12, 2221\u201336 (2019).","DOI":"10.2147\/DMSO.S216791"},{"key":"2834_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/nu10101502","volume":"10","author":"S Moreno-Fernandez","year":"2018","unstructured":"S. Moreno-Fernandez, M. Garces-Rimon, G. Vera, J. Astier, J.F. Landrier et al. High fat\/high glucose diet induces metabolic syndrome in an experimental rat model. Nutrients 10, 1\u201315 (2018)","journal-title":"Nutrients"},{"key":"2834_CR39","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1038\/hr.2011.222","volume":"35","author":"H Sasamura","year":"2012","unstructured":"H. Sasamura, H. Itoh, \u2018Memory\u2019 and \u2018legacy\u2019 in hypertension and lifestyle-related diseases. Hypertens Res 35, 272\u2013273 (2012)","journal-title":"Hypertens Res"},{"key":"2834_CR40","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1590\/S1807-59322008000500002","volume":"63","author":"N Lopes","year":"2008","unstructured":"N. Lopes, A.C. Zanini, A. Casella-Filho, A.C. Chagas, Metabolic syndrome patient compliance with drug treatment. Clinics 63, 573\u2013580 (2008)","journal-title":"Clinics"},{"key":"2834_CR41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1159\/000453037","volume":"26","author":"EA Alefishat","year":"2017","unstructured":"E.A. Alefishat, R.K. Abu Farha, M.M. Al-Debei, Self-reported adherence among individuals at high risk of metabolic syndrome: effect of knowledge and attitude. Med Princ Pract 26, 157\u2013163 (2017)","journal-title":"Med Princ Pract"},{"key":"2834_CR42","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/hr.2011.206","volume":"35","author":"N Togashi","year":"2012","unstructured":"N. Togashi, T. Maeda, H. Yoshida, M. Koyama, M. Tanaka et al. Angiotensin II receptor activation in youth triggers persistent insulin resistance and hypertension-a legacy effect? Hypertens Res 35, 334\u2013340 (2012)","journal-title":"Hypertens Res"},{"key":"2834_CR43","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s11906-011-0205-z","volume":"13","author":"M Volpe","year":"2011","unstructured":"M. Volpe, F. Cosentino, G. Tocci, F. Palano, F. Paneni, Antihypertensive therapy in diabetes: the legacy effect and RAAS blockade. Curr Hypertens Rep 13, 318\u2013324 (2011)","journal-title":"Curr Hypertens Rep"},{"key":"2834_CR44","doi-asserted-by":"publisher","first-page":"S317","DOI":"10.1016\/0168-8227(94)90269-0","volume":"24","author":"K Kawano","year":"1994","unstructured":"K. Kawano, T. Hirashima, S. Mori, T. Natori, OLETF (Otsuka Long-Evans Tokushima Fatty) rat: a new NIDDM rat strain. Diabetes Res Clin Pract 24, S317\u2013S320 (1994)","journal-title":"Diabetes Res Clin Pract"},{"key":"2834_CR45","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.2337\/diab.41.11.1422","volume":"41","author":"K Kawano","year":"1992","unstructured":"K. Kawano, T. Hirashima, S. Mori, Y. Saitoh, M. Kurosumi et al. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes 41, 1422\u20131428 (1992)","journal-title":"Diabetes"},{"key":"2834_CR46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/vhrm.2006.2.4.327","volume":"2","author":"HR Brunner","year":"2006","unstructured":"H.R. Brunner, Olmesartan medoxomil: current status of its use in monotherapy. Vasc Health Risk Manag 2, 327\u2013340 (2006)","journal-title":"Vasc Health Risk Manag"},{"key":"2834_CR47","doi-asserted-by":"publisher","first-page":"486","DOI":"10.5812\/ijem.3505","volume":"10","author":"A Ghasemi","year":"2012","unstructured":"A. Ghasemi, S. Zahediasl, Normality tests for statistical analysis: a guide for non-statisticians. Int J Endocrinol Metab 10, 486\u2013489 (2012)","journal-title":"Int J Endocrinol Metab"},{"key":"2834_CR48","first-page":"69","volume":"24","author":"MM Mukaka","year":"2012","unstructured":"M.M. Mukaka, Statistics corner: a guide to appropriate use of correlation coefficient in medical research. Malawi Med J 24, 69\u201371 (2012)","journal-title":"Malawi Med J"},{"key":"2834_CR49","doi-asserted-by":"publisher","first-page":"E529","DOI":"10.1152\/ajpendo.00610.2012","volume":"306","author":"P Zabielski","year":"2014","unstructured":"P. Zabielski, A. Blachnio-Zabielska, I.R. Lanza, S. Gopala, S. Manjunatha et al. Impact of insulin deprivation and treatment on sphingolipid distribution in different muscle subcellular compartments of streptozotocin-diabetic C57Bl\/6 mice. Am J Physiol Endocrinol Metab 306, E529\u2013E542 (2014)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2834_CR50","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1198\/sbr.2009.0025","volume":"1","author":"T Jaki","year":"2009","unstructured":"T. Jaki, M.J. Wolfsegger, A theoretical framework for estimation of AUCs in complete and incomplete sampling designs. Statistics in Biopharmaceutical Research 1, 176\u2013184 (2009)","journal-title":"Statistics in Biopharmaceutical Research"},{"key":"2834_CR51","doi-asserted-by":"publisher","first-page":"E494","DOI":"10.1152\/ajpendo.00042.2020","volume":"319","author":"H Heikela","year":"2020","unstructured":"H. Heikela, S.T. Ruohonen, M. Adam, R. Viitanen, H. Liljenback et al. Hydroxysteroid (17beta) dehydrogenase 12 is essential for metabolic homeostasis in adult mice. Am J Physiol Endocrinol Metab 319, E494\u2013E508 (2020)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2834_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.4097\/kjae.2017.70.4.407","volume":"70","author":"SK Kwak","year":"2017","unstructured":"S.K. Kwak, J.H. Kim, Statistical data preparation: management of missing values and outliers. Korean J Anesthesiol 70, 407\u2013411 (2017)","journal-title":"Korean J Anesthesiol"},{"key":"2834_CR53","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1111\/bph.12510","volume":"171","author":"H Muller-Fielitz","year":"2014","unstructured":"H. Muller-Fielitz, N. Hubel, M. Mildner, F.M. Vogt, J. Barkhausen et al. Chronic blockade of angiotensin AT(1) receptors improves cardinal symptoms of metabolic syndrome in diet-induced obesity in rats. Br J Pharmacol 171, 746\u2013760 (2014)","journal-title":"Br J Pharmacol"},{"key":"2834_CR54","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/1475-2840-6-26","volume":"6","author":"N Kitamura","year":"2007","unstructured":"N. Kitamura, Y. Takahashi, S. Yamadate, S. Asai, Angiotensin II receptor blockers decreased blood glucose levels: a longitudinal survey using data from electronic medical records. Cardiovasc Diabetol 6, 26 (2007)","journal-title":"Cardiovasc Diabetol"},{"key":"2834_CR55","doi-asserted-by":"publisher","first-page":"e20674","DOI":"10.1097\/MD.0000000000020674","volume":"99","author":"J Yao","year":"2020","unstructured":"J. Yao, X. Gong, X. Shi, S. Fan, J. Chen et al. The efficacy of angiotensin converting enzyme inhibitors versus angiotensin II receptor blockers on insulin resistance in hypertensive patients: a protocol for a systematic review and meta-analysis. Medicine 99, e20674 (2020)","journal-title":"Medicine"},{"key":"2834_CR56","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1291\/hypres.31.921","volume":"31","author":"T Sasaki","year":"2008","unstructured":"T. Sasaki, Y. Noda, Y. Yasuoka, H. Irino, H. Abe et al. Comparison of the effects of telmisartan and olmesartan on home blood pressure, glucose, and lipid profiles in patients with hypertension, chronic heart failure, and metabolic syndrome. Hypertens Res 31, 921\u2013929 (2008)","journal-title":"Hypertens Res"},{"key":"2834_CR57","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1038\/hr.2010.99","volume":"33","author":"L Ciccarelli","year":"2010","unstructured":"L. Ciccarelli, Angiotensin II receptor blockers and insulin resistance. Hypertens Res 33, 779 (2010)","journal-title":"Hypertens Res"},{"key":"2834_CR58","doi-asserted-by":"publisher","first-page":"100253","DOI":"10.1016\/j.aohep.2020.08.070","volume":"20","author":"JT Stefano","year":"2021","unstructured":"J.T. Stefano, L.V. Guedes, A.A.A. de Souza, D.S. Vanni, V.A.F. Alves et al. Usefulness of collagen type IV in the detection of significant liver fibrosis in nonalcoholic fatty liver disease. Ann Hepatol 20, 100253 (2021)","journal-title":"Ann Hepatol"},{"key":"2834_CR59","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/hepr.12710","volume":"47","author":"M Mizuno","year":"2017","unstructured":"M. Mizuno, T. Shima, H. Oya, Y. Mitsumoto, C. Mizuno et al. Classification of patients with non-alcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with liver histology and other fibrosis markers. Hepatol Res 47, 216\u2013225 (2017)","journal-title":"Hepatol Res"},{"key":"2834_CR60","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijcard.2012.02.008","volume":"157","author":"H Takagi","year":"2012","unstructured":"H. Takagi, T. Umemoto, Telmisartan reduces triglyceride levels over other angiotensin II receptor blockers: a meta-analysis of randomized head-to-head trials. Int J Cardiol 157, 403\u2013407 (2012)","journal-title":"Int J Cardiol"},{"key":"2834_CR61","doi-asserted-by":"publisher","first-page":"342648","DOI":"10.1155\/2013\/342648","volume":"2013","author":"YS Song","year":"2013","unstructured":"Y.S. Song, C.H. Fang, B.I. So, J.Y. Park, Y. Lee et al. Time course of the development of nonalcoholic Fatty liver disease in the Otsuka long-evans Tokushima Fatty rat. Gastroenterol Res Pract 2013, 342648 (2013)","journal-title":"Gastroenterol Res Pract"},{"key":"2834_CR62","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.ramb.2013.05.003","volume":"59","author":"MZ Teixeira","year":"2013","unstructured":"M.Z. Teixeira, Rebound effect of modern drugs: serious adverse event unknown by health professionals. Rev Assoc Med Bras 59, 629\u2013638 (2013)","journal-title":"Rev Assoc Med Bras"},{"key":"2834_CR63","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jhep.2009.01.018","volume":"50","author":"Y Nabeshima","year":"2009","unstructured":"Y. Nabeshima, S. Tazuma, K. Kanno, H. Hyogo, K. Chayama, Deletion of angiotensin II type I receptor reduces hepatic steatosis. J Hepatol 50, 1226\u20131235 (2009)","journal-title":"J Hepatol"},{"key":"2834_CR64","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1146\/annurev-nutr-071812-161220","volume":"34","author":"MY Pepino","year":"2014","unstructured":"M.Y. Pepino, O. Kuda, D. Samovski, N.A. Abumrad, Structure-function of CD36 and importance of fatty acid signal transduction in fat metabolism. Annu Rev Nutr 34, 281\u2013303 (2014)","journal-title":"Annu Rev Nutr"},{"key":"2834_CR65","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.mam.2012.07.010","volume":"34","author":"CM Anderson","year":"2013","unstructured":"C.M. Anderson, A. Stahl, SLC27 fatty acid transport proteins. Mol Aspects Med 34, 516\u2013528 (2013)","journal-title":"Mol Aspects Med"},{"key":"2834_CR66","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s00535-019-01633-2","volume":"55","author":"K Enooku","year":"2020","unstructured":"K. Enooku, T. Tsutsumi, M. Kondo, N. Fujiwara, T. Sasako et al. Hepatic FATP5 expression is associated with histological progression and loss of hepatic fat in NAFLD patients. J Gastroenterol 55, 227\u2013243 (2020)","journal-title":"J Gastroenterol"},{"key":"2834_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.93626","volume":"3","author":"ME Moreno-Fernandez","year":"2018","unstructured":"M.E. Moreno-Fernandez, D.A. Giles, T.E. Stankiewicz, R. Sheridan, R. Karns et al. Peroxisomal beta-oxidation regulates whole body metabolism, inflammatory vigor, and pathogenesis of nonalcoholic fatty liver disease. JCI Insight 3, 1\u201319 (2018)","journal-title":"JCI Insight"},{"key":"2834_CR68","doi-asserted-by":"publisher","first-page":"11245","DOI":"10.1073\/pnas.0404297101","volume":"101","author":"G Chen","year":"2004","unstructured":"G. Chen, G. Liang, J. Ou, J.L. Goldstein, M.S. Brown, Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci USA 101, 11245\u201311250 (2004)","journal-title":"Proc Natl Acad Sci USA"},{"key":"2834_CR69","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.redox.2017.10.005","volume":"14","author":"M Thorwald","year":"2018","unstructured":"M. Thorwald, R. Rodriguez, A. Lee, B. Martinez, J. Peti-Peterdi et al. Angiotensin receptor blockade improves cardiac mitochondrial activity in response to an acute glucose load in obese insulin resistant rats. Redox Biol 14, 371\u2013378 (2018)","journal-title":"Redox Biol"},{"key":"2834_CR70","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41387-018-0045-x","volume":"8","author":"J Yu","year":"2018","unstructured":"J. Yu, K. Loh, Z.Y. Song, H.Q. Yang, Y. Zhang et al. Update on glycerol-3-phosphate acyltransferases: the roles in the development of insulin resistance. Nutr Diabetes 8, 34 (2018)","journal-title":"Nutr Diabetes"},{"key":"2834_CR71","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1194\/jlr.R800018-JLR200","volume":"49","author":"CL Yen","year":"2008","unstructured":"C.L. Yen, S.J. Stone, S. Koliwad, C. Harris, R.V. Farese Jr, Thematic review series: glycerolipids DGAT enzymes and triacylglycerol biosynthesis. J Lipid Res 49, 2283\u20132301 (2008)","journal-title":"J Lipid Res"},{"key":"2834_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/children4060046","volume":"4","author":"FM Perla","year":"2017","unstructured":"F.M. Perla, M. Prelati, M. Lavorato, D. Visicchio, C. Anania, The role of lipid and lipoprotein metabolism in non-alcoholic fatty liver disease. Children 4, 1\u201314 (2017)","journal-title":"Children"},{"key":"2834_CR73","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.tem.2011.04.007","volume":"22","author":"SH Choi","year":"2011","unstructured":"S.H. Choi, H.N. Ginsberg, Increased very low density lipoprotein (VLDL) secretion, hepatic steatosis, and insulin resistance. Trends Endocrinol Metab 22, 353\u2013363 (2011)","journal-title":"Trends Endocrinol Metab"},{"key":"2834_CR74","doi-asserted-by":"publisher","first-page":"9685607","DOI":"10.1155\/2019\/9685607","volume":"2019","author":"R Arriga","year":"2019","unstructured":"R. Arriga, F. Pacifici, B. Capuani, A. Coppola, A. Orlandi et al. Peroxiredoxin 6 is a key antioxidant enzyme in modulating the link between glycemic and lipogenic metabolism. Oxid Med Cell Longev 2019, 9685607 (2019)","journal-title":"Oxid Med Cell Longev"},{"key":"2834_CR75","doi-asserted-by":"publisher","first-page":"E852","DOI":"10.1152\/ajpendo.00193.2019","volume":"317","author":"A McCullough","year":"2019","unstructured":"A. McCullough, S.F. Previs, J. Dasarathy, K. Lee, A. Osme et al. HDL flux is higher in patients with nonalcoholic fatty liver disease. Am J Physiol Endocrinol Metab 317, E852\u2013E862 (2019)","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2834_CR76","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1681\/ASN.2004080649","volume":"16","author":"Y Nagai","year":"2005","unstructured":"Y. Nagai, L. Yao, H. Kobori, K. Miyata, Y. Ozawa et al. Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats. J Am Soc Nephrol 16, 703\u2013711 (2005)","journal-title":"J Am Soc Nephrol"},{"key":"2834_CR77","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1172\/JCI118173","volume":"96","author":"DE Greenwalt","year":"1995","unstructured":"D.E. Greenwalt, S.H. Scheck, T. Rhinehart-Jones, Heart CD36 expression is increased in murine models of diabetes and in mice fed a high fat diet. J Clin Invest 96, 1382\u20131388 (1995)","journal-title":"J Clin Invest"},{"key":"2834_CR78","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/89969","volume":"7","author":"E Griffin","year":"2001","unstructured":"E. Griffin, A. Re, N. Hamel, C. Fu, H. Bush et al. A link between diabetes and atherosclerosis: glucose regulates expression of CD36 at the level of translation. Nat Med 7, 840\u2013846 (2001)","journal-title":"Nat Med"},{"key":"2834_CR79","doi-asserted-by":"publisher","first-page":"22186","DOI":"10.1074\/jbc.M803510200","volume":"283","author":"H Doege","year":"2008","unstructured":"H. Doege, D. Grimm, A. Falcon, B. Tsang, T.A. Storm et al. Silencing of hepatic fatty acid transporter protein 5 in vivo reverses diet-induced non-alcoholic fatty liver disease and improves hyperglycemia. J Biol Chem 283, 22186\u201322192 (2008)","journal-title":"J Biol Chem"},{"key":"2834_CR80","first-page":"1175","volume":"21","author":"K Meyer","year":"2002","unstructured":"K. Meyer, Y. Jia, W.Q. Cao, P. Kashireddy, M.S. Rao, Expression of peroxisome proliferator-activated receptor alpha, and PPARalpha regulated genes in spontaneously developed hepatocellular carcinomas in fatty acyl-CoA oxidase null mice. Int J Oncol 21, 1175\u20131180 (2002)","journal-title":"Int J Oncol"},{"key":"2834_CR81","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1042\/bj3200345","volume":"320","author":"S Eaton","year":"1996","unstructured":"S. Eaton, K. Bartlett, M. Pourfarzam, Mammalian mitochondrial beta-oxidation. Biochem J 320, 345\u2013357 (1996)","journal-title":"Biochem J"},{"key":"2834_CR82","first-page":"351","volume":"20","author":"M Kohjima","year":"2007","unstructured":"M. Kohjima, M. Enjoji, N. Higuchi, M. Kato, K. Kotoh et al. Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med 20, 351\u2013358 (2007)","journal-title":"Int J Mol Med"},{"key":"2834_CR83","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/S0163-7827(03)00051-1","volume":"43","author":"RA Coleman","year":"2004","unstructured":"R.A. Coleman, D.P. Lee, Enzymes of triacylglycerol synthesis and their regulation. Prog Lipid Res 43, 134\u2013176 (2004)","journal-title":"Prog Lipid Res"},{"key":"2834_CR84","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.1194\/jlr.R800053-JLR200","volume":"50","author":"CA Nagle","year":"2009","unstructured":"C.A. Nagle, E.L. Klett, R.A. Coleman, Hepatic triacylglycerol accumulation and insulin resistance. J Lipid Res 50, S74\u2013S79 (2009)","journal-title":"J Lipid Res"},{"key":"2834_CR85","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1002\/hep.27695","volume":"61","author":"BM Arendt","year":"2015","unstructured":"B.M. Arendt, E.M. Comelli, D.W. Ma, W. Lou, A. Teterina et al. Altered hepatic gene expression in nonalcoholic fatty liver disease is associated with lower hepatic n-3 and n-6 polyunsaturated fatty acids. Hepatology 61, 1565\u20131578 (2015)","journal-title":"Hepatology"},{"key":"2834_CR86","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1002\/hep.22980","volume":"50","author":"CJ Villanueva","year":"2009","unstructured":"C.J. Villanueva, M. Monetti, M. Shih, P. Zhou, S.M. Watkins et al. Specific role for acyl CoA:Diacylglycerol acyltransferase 1 (Dgat1) in hepatic steatosis due to exogenous fatty acids. Hepatology 50, 434\u2013442 (2009)","journal-title":"Hepatology"},{"key":"2834_CR87","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/75651","volume":"25","author":"SJ Smith","year":"2000","unstructured":"S.J. Smith, S. Cases, D.R. Jensen, H.C. Chen, E. Sande et al. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat. Nat Genet 25, 87\u201390 (2000)","journal-title":"Nat Genet"},{"key":"2834_CR88","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1101\/gad.12.20.3182","volume":"12","author":"I Shimomura","year":"1998","unstructured":"I. Shimomura, R.E. Hammer, J.A. Richardson, S. Ikemoto, Y. Bashmakov et al. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-1c in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 12, 3182\u20133194 (1998)","journal-title":"Genes Dev"},{"key":"2834_CR89","doi-asserted-by":"publisher","first-page":"E10417","DOI":"10.1073\/pnas.1808968115","volume":"115","author":"T Kodama","year":"2018","unstructured":"T. Kodama, J. Yi, J.Y. Newberg, J.C. Tien, H. Wu et al. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis. Proc Natl Acad Sci USA 115, E10417\u2013E10426 (2018)","journal-title":"Proc Natl Acad Sci USA"},{"key":"2834_CR90","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","volume":"134","author":"E Fabbrini","year":"2008","unstructured":"E. Fabbrini, B.S. Mohammed, F. Magkos, K.M. Korenblat, B.W. Patterson et al. Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease. Gastroenterology 134, 424\u2013431 (2008)","journal-title":"Gastroenterology"},{"key":"2834_CR91","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1172\/JCI6246","volume":"103","author":"JD Horton","year":"1999","unstructured":"J.D. Horton, H. Shimano, R.L. Hamilton, M.S. Brown, J.L. Goldstein, Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL. J Clin Invest 103, 1067\u20131076 (1999)","journal-title":"J Clin Invest"},{"key":"2834_CR92","unstructured":"R.A. Cox, M.R. Garcia-Palmieri. Cholesterol, triglycerides, and associated lipoproteins. In: H.K. Walker, W.D. Hall, J.W. Hurst (eds) Clinical methods: the history, physical, and laboratory examinations (Butterworth Publishers, Boston, 1990)"},{"key":"2834_CR93","unstructured":"K.R. Feingold. Introduction to Lipids and Lipoproteins. In: K.R. Feingold, B. Anawalt, A. Boyce, G. Chrousos, W.W. de Herder, et al. (eds) Endotext. (MDText.com, Inc., South Dartmouth, MA, 2000)"},{"key":"2834_CR94","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1089\/ars.2012.4946","volume":"19","author":"A Nabeshima","year":"2013","unstructured":"A. Nabeshima, S. Yamada, X. Guo, A. Tanimoto, K.Y. Wang et al. Peroxiredoxin 4 protects against nonalcoholic steatohepatitis and type 2 diabetes in a nongenetic mouse model. Antioxid Redox Signal 19, 1983\u20131998 (2013)","journal-title":"Antioxid Redox Signal"},{"key":"2834_CR95","doi-asserted-by":"publisher","first-page":"2270","DOI":"10.1002\/pmic.200300810","volume":"4","author":"GM Schmid","year":"2004","unstructured":"G.M. Schmid, V. Converset, N. Walter, M.V. Sennitt, K.Y. Leung et al. Effect of high-fat diet on the expression of proteins in muscle, adipose tissues, and liver of C57BL\/6 mice. Proteomics 4, 2270\u20132282 (2004)","journal-title":"Proteomics"},{"key":"2834_CR96","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1089\/ars.2010.3766","volume":"16","author":"JY Huh","year":"2012","unstructured":"J.Y. Huh, Y. Kim, J. Jeong, J. Park, I. Kim et al. Peroxiredoxin 3 is a key molecule regulating adipocyte oxidative stress, mitochondrial biogenesis, and adipokine expression. Antioxid Redox Signal 16, 229\u2013243 (2012)","journal-title":"Antioxid Redox Signal"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-021-02834-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-021-02834-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,5]],"date-time":"2023-02-05T10:18:29Z","timestamp":1675592309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-021-02834-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,29]]},"references-count":96,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["2834"],"URL":"https:\/\/doi.org\/10.1007\/s12020-021-02834-7","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,29]]},"assertion":[{"value":"6 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All experimental procedures were reviewed and approved by the institutional animal care and use committees of the Kagawa Medical University (Japan) and the University of California, Merced (USA).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}